Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology,...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, underpric
Target Price
The average target price of GUBRA.CO is 468 and suggests 10% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to
Buy
Sell